Compile Data Set for Download or QSAR
Report error Found 31 Enz. Inhib. hit(s) with all data for entry = 929
Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199539((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: 0.462nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199092(US9670229, 6 | (1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1...)
Affinity DataIC50: 0.510nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199498(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.600nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299207(US10125145, Cpd. No. 5 | (1R,5S,7S)-3-oxa-9-azabic...)
Affinity DataIC50: 0.620nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199485(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.650nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199522((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.650nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199504(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50: 0.662nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199484((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.680nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199096(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.690nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199501(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50: 0.720nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199541((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: 0.745nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199513((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 0.75nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199094((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.810nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199500(n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 0.882nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199091((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.950nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199094((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 0.960nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199524((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 1.01nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199521((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 1.10nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199092(US9670229, 6 | (1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1...)
Affinity DataIC50: 1.10nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199518((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 1.20nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299216(US10125145, Cpd. No. 14 | N-((1R,5S,7S)-9-methyl-3...)
Affinity DataIC50: 1.34nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199544(3-(3-(((1r,5s,7s)-9-methyl- 3-oxa-9-azabicyclo[3.3...)
Affinity DataIC50: 1.36nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199527((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50: 1.39nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199533((1r,5s,7s)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50: 1.44nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199520((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 1.5nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299220(US10125145, Cpd. No. 18 | (1R,5S,7S)-9-methyl-3-ox...)
Affinity DataIC50: 2.01nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199538((1r,5s,7s)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50: 2.04nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199512((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50: 2.5nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199110((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50: 2.86nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299221(US10125145, Cpd. No. 19 | (1R,5S,7S)-3-oxa-9-azabi...)
Affinity DataIC50: 3.68nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199542((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: 1.00E+3nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/12/2019
Entry Details
US Patent